Navigation Links
Brain Tumor Drug in Frogs A New Report

A synthetic version of a molecule found in the egg cells of the Northern Leopard frog (Rana pipiens) could provide the world with the first drug treatment for brain tumours.

The molecule Amphinase,recognises the sugary coating found on a tumour cell and binds to its surface before invading the cell and inactivating the RNA it contains, causing the tumour to die.

In new research published in the Journal of Molecular Biology, scientists from the University of Bath (UK) and Alfacell Corporation (USA) describe the first complete analysis of the structural and chemical properties of the molecule.

Although it could potentially be used as a treatment for many forms of cancer, Amphinase offers greatest hope in the treatment of brain tumours, for which complex surgery and chemotherapy are the only current treatments.

This is a very exciting molecule, said Professor Ravi Acharya, from the Department of Biology & Biochemistry at the University of Bath.It is rather like Mother Natures very own magic bullet for recognising and destroying cancer cells.

It is highly specific at hunting and destroying tumour cells, is easily synthesised in the laboratory and offers great hope as a therapeutic treatment of the future.Amphinase is a version of a ribonuclease enzyme that has been isolated from the oocytes (egg cells) of the Northern Leopard frog.

Ribonucleases are a common type of enzyme found in all organisms. They are responsible for tidying up free-floating strands of RNA cells by latching on to the molecule and cutting it into smaller sections.

In areas of the cell where the RNA is needed for essential functions, ribonucleases are prevented from working by inhibitor molecules. But because Amphinase is an amphibian ribonuclease, it can evade the mammalian inhibitor molecules to attack the cancer cells.

As a treatment, it is most likely to be injected into the area where it is needed. It will have no effect on other cells because it is only capable of recognising and binding to the sugar coating of tumour cells.

Amphinase is in the very early stages of development, so it is likely to be several years and many trials before it could be developed into a treatment for patients, said Professor Acharya and his colleagues Drs Umesh Singh and Daniel Holloway.

Having said that, the early data is promising and through this study we have provided the kind of information needed if approval for use is requested in the future.Amphinase is the second anti-tumour ribonuclease to be isolated by Alfacell Corporation from Rana pipiens oocytes.

The other, ONCONASE(R) (ranpirnase), is currently in late-stage clinical trials as a treatment for unresectable malignant mesothelioma, a rare and fatal form of lung cancer, and in Phase I/II clinical trials in non-small cell lung cancer and other solid tumours.

We are pleased with the superb work performed by Professor Acharya and his talented team at the University of Bath, commented Kuslima Shogen, Alfacells chairman and chief executive officer.

Their work is critical to the continued development and understanding of our family of novel ribonuclease based therapeutics with the potential to help patients suffering from cancer and other dismal diseases.The company is now working on pre-clinical trials of Amphinase with a view to beginning clinical trials in the future.


'"/>




Related medicine news :

1. Use of Cellular Phones associated with Increased risk of Brain Tumors
2. Brain death – How to cope with it
3. “Brain fingerprinting”- The new lie detectr
4. Nasal Spray Could Take Drugs Direct to Brain.
5. Virus Combats Brain Tumour
6. Nasal Spray Could Take Drugs Directly to Brain
7. Control of anger disorder connected to Brain Dysfunction
8. High Levels of Protein Linked to Brain Shrinkage
9. Brain damage affects artistic skill
10. Brain cells protected by new compounds
11. Brain changes observed in people with sleep apnoea
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, was ... his family verbally and physically. , “When something upset him, he couldn’t control his emotions,” ... He would throw rocks at my other children and say he was going to kill ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, P.A. announced that ... chosen by their peers for this recognition are considered among the top 2 percent ... special honors as members of this year’s Legal Elite Hall of Fame: Miami ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, CA is ... Road To Recovery® program to drive cancer patients to and from their cancer treatments. ... the highest quality of life and ongoing independence. Getting to and from medical ...
(Date:6/24/2016)... Plano, TX (PRWEB) , ... June 24, 2016 , ... ... taking part in Genome magazine’s Code Talker Award, an essay contest in which patients ... for an award to be presented at the 2016 National Society of Genetic Counselors ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... Living, is proud to recognize Dr. Barry M. Weintraub as a prominent plastic ... most beautiful women in the world, and the most handsome men, look naturally ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... 23, 2016 The vast majority of dialysis ... facility.  Treatments are usually 3 times a week, with ... including travel time, equipment preparation and wait time.  This ... grueling for patients who are elderly and frail.  Many ... and rehabilitation centers for some duration of time. ...
(Date:6/23/2016)... Tenn. , June 23, 2016 /PRNewswire/ ... automating, integrating and transforming the patient payment ... of several innovative new products and services ... of its revenue cycle offerings. These award-winning ... more efficient workflows, remain compliant in an ...
(Date:6/23/2016)... , June 23, 2016  The National ... has joined the health policy research organization as ... Romano , MD, senior vice president and chief ... company,s representative on the NPC Board of Directors. ... pleased that Mallinckrodt has joined us in support ...
Breaking Medicine Technology: